Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects

Abstract

Dear Editor, Genetic engineering of T cells to express chimeric antigen receptors (CARs) is an efficient approach for clinical therapy of hematological malignancies (Kuwana et al., 1987; Eshhar et al., 1993; Barrett et al., 2014). The CARs endow T cells with the ability to recognize specific antigens and bind them in an MHC-independent manner, thereby overcoming some of the mechanisms that mediate tumor immune escape. In addition, by providing co-stimulatory signals, CARs endow T cells with enhanced cytotoxicity and persistence compared with primary T cells. A typical CAR comprises a single-chain variable fragment (scFv) derived from a monoclonal antibody (mAb) for antigen recognition and signaling domains for co-activation (Eshhar et al., 1993; Sadelain et al., 2013). To date, CAR-T cell therapy has been most effective in immunotherapy of CD19+ B cell acute lymphoblastic leukemia, with a complete response in more than 75% of cases (Sadelain et al., 2013). However, there are still some challenges for CAR-T-mediated treatments. Side effects like off-targeting, cytokine release syndrome (CRS) and neuronal toxicities have been reported, and these may induce lethal responses (Morgan et al., 2010; Park et al., 2011). In addition, no response, incomplete tumor regression, and tumor recurrence were also observed after CAR-T treatment. For example, 10%–20% of patients were non-responsive to CD19 CAR-T clinical therapy (Lee et al., 2015; Park et al., 2018). Even in cases with a complete response, about 50% of them suffered tumor recurrence in one year, and one third of them had a CD19+ relapse (Maude et al., 2018; Orlando et al., 2018). These disappointing results are associated with early CAR-T cell disappearance or poor cell function, which leads to incomplete tumor regression or loss of long-term antitumor effects. Cytokines are important factors for T cell development and homeostasis. In addition to the TCR and costimulatory receptors, cytokines provide stimulatory signals for full T cell activation, and have pleiotropic effects on T cell proliferation, differentiation and function. Currently, IL-2 is the main cytokine used to culture cells for adoptive cell therapy, as it plays an important role in the proliferation and functional effect of T cells. However, T cells cultured with IL-2 are phenotypically heterogeneous, being predominantly composed of effector memory cells which have sufficient functional effect but are sensitive to death. IL-7 has a critical role in the development and maturation of T cells. It promotes the generation of naïve and central memory T cell subsets and regulates their homeostasis. IL-15 mediates the formation and homeostasis of CD8 memory T cells. It has been reported that IL-7 and IL-15 are able to instruct T cells toward memory stem-like phenotypes, which are less differentiated and have a superior capacity for expansion and survival (Cieri et al., 2013). Here, we systematically compared the effects of IL-7/IL-15 and IL-2 on the expansion, apoptosis and anti-tumor responses of CAR-T cells. We first constructed the anti-CD19 CAR (19BB-CAR) using an anti-CD19 mAb (clone FMC63)-derived scFv linked to the CD8α hinge and transmembrane regions, followed by a 4-1BB intracellular signaling domain and the CD3ζ signaling moiety. The 19BB-CAR and enhanced green fluorescent protein (eGFP) sequences were ligated and subcloned into the lentiviral vector FUW with a substitutive EF1α promoter (Fig. S1A). The cultured primary T cells were stimulated with anti-CD3/anti-CD28 Dynabeads and cytokine IL-2 before transduction with 19BB-CAR lentiviral particles. Using Protein L binding to the variable immunoglobulin light chains of the CAR, we found that CAR expression is directly correlated to eGFP expression (Fig. S1B). The CAR was highly expressed in IL-2-cultured T cells three days after infection (Fig. S1C). The CAR-T cells were expanded 100-fold in 2 weeks under IL-2 stimulation (Fig. S1D). To test the specificity of 19BB-CAR-T cells, we co-incubated them with two human leukemia cell lines, Raji (CD19+) and K562 (CD19−). The secretion of IL-2, IFN-γ and TNF-α by 19BB-CAR-T cells was significantly increased upon co-incubation with CD19+ Raji but not CD19− K562 cells (Fig. S1E). Accordingly, cytotoxicity assays showed that 19BB-CAR-T cells specifically lysed CD19+ Raji but not CD19− K562 cells (Fig. S1F). These data suggest that 19BB-CAR-T cells specifically recognize the CD19 molecule. To evaluate the anti-tumor effects of 19BB-CAR-T cells cultured using IL-2 in vivo, CD19+ Raji cells labeled with fluorescent luciferase fusion protein were engrafted to immunodeficient mice for lymphoma formation. Then human T cells transduced with 19BB-CAR or GFP vectors were infused into the mice (Fig. S1G). Mice receiving 19BB-CAR-T cells showed effective tumor regression, while mice infused with T cells harboring empty vector had progressive tumor growth (Fig. S1G–H). Long-term monitoring showed that mice infused with 19BB-CAR-T cells had a significantly higher survival rate and longer survival period compared with mice receiving empty-vector T cells (Fig. S1I). These data provide evidence that 19BB-CAR-T cells can effectively remove tumor cells in vivo. However, lymphoma recurrence was observed in some mice treated with 19BB-CAR-T cells, and nearly half of the 19BB-CAR-T mice died within 60 days of infusion due to the tumor burden. These phenotypes are consistent with clinical data, which calls for optimization of CAR-T cells for more efficient tumor killing. Proliferation and apoptosis are two major aspects to be considered for in vitro expansion of CAR-T cells. In the two-week in vitro culture assays, we found that the 19BB-CAR-T cells were more efficiently expanded with IL-7/IL-15 than with IL-2 (Fig. 1A). Satisfactorily, there were no differences in the CAR transduction efficiency of T cells cultured in IL-2 or IL-7/IL-15 (Fig. S2). 19BB-CAR-T cells cultured with IL-7/IL-15 showed higher proliferation and a lower apoptosis rate compared to cells cultured with IL-2 (Fig. 1B and 1C). Consistent with this phenotype, the expression of the anti-apoptosis protein BCL-2 is higher in 19BB-CAR-T cells cultured with IL-7/IL-15 than with IL-2 (Fig. 1D). Together, these data suggest that IL-7/IL-15 provide a better environment than IL-2 for CAR-T cell expansion. IL-7/IL-15 supplements induce increased proliferation of 19BB-CAR-T cells and mediate superior anti-tumor effects in vivo. (A) Ex vivo proliferation of 19BB-CAR-T cells following stimulation with anti-CD3/CD28 antibodies and cytokines IL-7/IL-15 or IL-2. The results are from 4 independent experiments, **P < 0.01. (B) CytoTell Blue staining to detect the proliferation of 19BB-CAR-T cells cultured with IL-7/IL-15 or IL-2 at day 11. The results are from 4 independent experiments, *P < 0.05. (C) 19BB-CAR-T cells cultured with IL-7/IL-15 have a lower apoptosis rate than cells cultured with IL-2. Annexin V and PI were used to determine the proportion of apoptotic cells after a two-week culture. Data are shown as mean ± SEM from 3 independent experiments. *P < 0.05. (D) 19BB-CAR-T cells cultured with IL-7/IL-15 show increased expression of the anti-apoptosis protein BCL-2 compared to cells cultured with IL-2. Cells were cultured with IL-7/IL-15 or IL-2 for 11 days and then analyzed by flow cytometry using anti-BCL-2 antibody. (E) ELISA detection of IL-2, IFN-γ and TNF-α secretion by 19BB-CAR-T cells expanded with IL-7/IL-15 or IL-2. The cells were stimulated by Raji or K562 cells for 24 hours. Data are presented as mean ± SEM from 3 independent experiments. ns, not significant. (F) 19BB-CAR-T cells expanded with IL-7/IL-15 or IL-2 have similar cytotoxicity. Data are presented as mean ± SEM from 3 independent experiments. (G) Representative images of Raji/LUC tumor regression in mice treated for 4 weeks with 19BB-CAR-T cells expanded with IL-7/IL-15 or IL-2, n = 4 per group. (H) Mean photon flux ± SEM of bioluminescent signals in mice receiving infusions of 19BB-CAR-T cells expanded with IL-7/IL-15 or IL-2. Data are from 3 independent experiments, n = 4 per group. (I) Survival curves of mice receiving 19BB-CAR-T cells expanded with IL-7/IL-15 or IL-2. Data are from 3 independent experiments, n = 4 per group. *P < 0.05 (IL-7/IL-15 vs. IL-2). We next investigated the functional properties of CAR-T cells expanded in IL-7/IL-15 or IL-2. The results showed no significant difference in immune cytokine release (IL-2, IFN-γ, TNF-α) or specific lysis (Fig. 1E and 1F). We also investigated the cytokine secretion and cytotoxicity of 19BB-CAR-T cells after serial antigen stimulation to mimic tumor encounter in vivo, and found no significant differences between the two culture systems (Fig. S3A–C). We then infused the IL-7/IL-15- or IL-2-expanded 19BB-CAR-T cells into mice with lymphoma for detection of tumor suppression effects. The antitumor effects were similar in the first 3 weeks. However, the 19BB-CAR-T cells expanded in IL-7/IL-15 showed superior anti-tumor activity, and the long-term survival of the tumor burden mice was significantly improved (Fig. 1G–I). According to their surface expression of CD45RA and CD62L, primary T cells are divided into four differentiation states: naïve T cells (TN) (CD45RA+CD62L+), central memory T cells (TCM) (CD45RA−CD62L+), effector memory T cells (TEM) (CD45RA−CD62L−), and CD45RA+ effector memory T cells (TRAEM) (CD45RA+CD62L−) as reported (Cieri et al., 2013). We found that CD8+ CAR-T cell expansion was enhanced during culture with IL-7/IL-15 (Fig. 2A). IL-7/IL-15 induced an increase of the CD8+ naïve T cell and central memory T cell populations, while IL-2 enhanced the CD8+ effector memory T cell population in vitro (Fig. 2B–C). These data indicate that IL-7/IL-15-expanded 19BB-CAR-T cells, which have undergone limited differentiation, may engraft into tumor-bearing mice more efficiently. 19BB-CAR-T cells cultured with IL-7/IL-15 show a superi

Cited by papers we hold 8

• Impact of Manufacturing Procedures on CAR T Cell Functionality · 2022
  No notice
• CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges · 2022
  No notice
• Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy · 2022
  No notice
• Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives · 2021
  No notice
• Counteracting CAR T cell dysfunction · 2021
  No notice
• Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression · 2020
  No notice
• Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives · 2020
  No notice
• Gene modification strategies for next-generation CAR T cells against solid cancers · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.